Multiple Myeloma: A Practical Guide to Current Management

Faculty Disclosures
Dr. Ivan Borrello
Johns Hopkins University
The discussant, Ivan Borello, MD, receives
grant/research support from Cell Genetics.
Dr. Philip Greipp
Mayo Clinic
The discussant, Philip Greipp, MD, to the best
of his knowledge has no conflict of interest.
Dr. Mohamad Hussein
Cleveland Clinic Foundation
The discussant, Mohamad Hussein, MD, receives
grant/research support from Alza, Ortho Biotech,
Celgene, and Amgen.
Dr. Jayesh Mehta
Northwestern University Medical School
The discussant, Jayesh Mehta, MD, receives
grant/research support from Celgene and Millennium.
Professor Gareth Morgan
Royal Marsden Hospital
The discussant, Gareth Morgan, PhD, to the best
of his knowledge has no conflict of interest.
Dr. Robert Orlowski
University of North Carolina at Chapel Hill
The discussant, Robert Orlowski, MD, to the best
of his knowledge has no conflict of interest.
Dr. Miles Prince
Peter MacCallum Cancer Centre
The discussant, Miles Prince, MBBS, is a consultant
for Amgen (Australia), Celgene, Janssen-Cilog
(Australia), and Novartis (Australia).
Dr. Paul Richardson
Dana-Farber Cancer Institute
The discussant, Paul Richardson, MD, is an educator
for Millennium and Celgene.
Dr. Seema Singhal
Northwestern University Medical School
The discussant, Seema Singhal, MD, is an educator
for Celgene and Millennium.
Dr. Keith Stewart
Mayo Clinic
The discussant, Keith Stewart, MD, is a consultant
for Ortho Biotech and has stock in Celgene.
Dr. Robert Vescio
Cedars-Sinai Medical Center
The discussant, Robert Vescio, MD, receives
grant/research support from Celgene and Millennium.
3